Idera Pharmaceuticals, Inc.

Sage Therapeutics, Inc. has a lot to figure out in the coming weeks, now that the US Food and Drug Administration has approved Zurzuvae (zuranolone) for postpartum depression (PPD) but rejected the d

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Calls On SyntheX, Autolus In Protei

Merck KGaA is homing in on five candidates with first-in-class (FIC) potential across a range of therapeutic areas and stages ahead of an anticipated market boost in 2025. The German giant plans to f

Shares in Idera Pharmaceuticals, Inc. have taken a bashing after a late-stage trial showed that adding its investigational Toll-like receptor (TLR) 9 agonist tilsotolimod to Bristol Myers Squibb Co